Skip to main content

Table 1 Patient and [18F]PSMA-1007-PET/CT characteristics

From: Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer

Characteristics

Value

 

Total number of available observations

Age (years)

  

175

 Mean ± SDa

69 ± 8.8

  

 Median (range)

70 (46–88)

  

Neoadjuvant treatment

13

9.5%

137

Primary treatment

  

137

 Radical prostatectomy

107

78%

 

 EBRTb

12

8.8%

 

 Androgen deprivation therapy

10

7.3%

 

 Brachytherapy

7

5.1%

 

 High Intensity Focused Ultrasound

1

0.7%

 

Adjuvant external beam radiation therapy

30

22%

137

Prior androgen deprivation therapy

83

61%

137

Ongoing androgen deprivation therapy

42

24%

175

Salvage therapy

  

137

 No salvage surgery or EBRT

76

55%

 

 Salvage surgery

13

9.5%

 

 EBRT

39

28%

 

 Salvage surgery and EBRT

9

6.6%

 

Pathologic primary tumour staging

  

107

 pT2

44

41%

 

 pT3

60

56%

 

 pT4

3

2.8%

 

Pathologic regional lymph node staging

  

79

 pN0

57

72%

 

 pN1

22

28%

 

Positive surgical margin at radical prostatectomy

41

41%

101

Number of positive lymph nodes removed at primary treatment

  

78

 Median (range)

0 (0–18)

  

Gleason score

  

136

 5

1

0.7%

 

 6

9

6.6%

 

 7

67

49%

 

 8

33

24%

 

 9

26

19%

 

PSA value after radical prostatectomy (ng/ml)

  

102

 Mean ± SD

0.4 ± 1.6

  

 Median (range)

0.04 (0–12)

  

PSA value at PET scan (ng/ml)

  

175

 Mean ± SD

11.1 ± 47.5

  

 Median (range)

1.6 (0.07–429)

  

PSA doubling time (months)

  

171

 Mean ± SD

9.5 ± 10.1

  

 Median (range)

6.7 (0.8–96.9)

  

PSA velocity (ng/ml/month)

  

171

 Mean ± SD

1.6 ± 9.8

  

 Median (range)

0.1 (0–114.5)

  
  1. aStandard deviation
  2. bExternal beam radiation therapy